SEMA3F

Across TCGA pan-cancer cohorts, SEMA3F Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated SEMA3F data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SEMA3F Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEMA3F expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

SCLC, UCEC, and ESCA are the cancer types where SEMA3F Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.178	0.631	.005	18	view →
UCEC	DFS	Median	All	1.000	0.829	.014	16	view →
ESCA	OS	Median	II,III,IV	0.136	0.687	.001	12	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
READ	DFS	Median	All	0.082	0.845	<.001	9	view →
COAD	DFS	Median	All	0.121	0.573	<.001	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	DFS	Median	All	0.208	0.731	<.001	3	view →
LIHC	OS	Median	All	0.169	0.669	.032	3	view →
SKCM	DFS	Median	III,IV	0.842	0.226	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

SEMA3F–SCLC (DFS)

Open the SCLC breakdown →